Specificity of phosphorylation responses to MAP kinase pathway inhibitors in melanoma cells.

about

Specificity of phosphorylation responses to MAP kinase pathway inhibitors in melanoma cells.

Item

http://www.wikidata.org/entity/Q47279069

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Specificity of phosphorylation ...... inhibitors in melanoma cells.

@en

Specificity of phosphorylation ...... inhibitors in melanoma cells.

@nl

type

Item

label

Specificity of phosphorylation ...... inhibitors in melanoma cells.

@en

Specificity of phosphorylation ...... inhibitors in melanoma cells.

@nl

prefLabel

Specificity of phosphorylation ...... inhibitors in melanoma cells.

@en

Specificity of phosphorylation ...... inhibitors in melanoma cells.

@nl

P1476

Specificity of phosphorylation ...... inhibitors in melanoma cells.

@en

P2093

Christopher C Ebmeier

http://www.w3.org/2001/XMLSchema#string

Scott A Stuart

http://www.w3.org/2001/XMLSchema#string

Thomas Lee

http://www.w3.org/2001/XMLSchema#string

William M Old

http://www.w3.org/2001/XMLSchema#string

P2860

Specificity of linear motifs that bind to a common mitogen-activated protein kinase docking groove

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases

STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation

MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway

Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs

Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo

Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479

Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

P304

550-564

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/MCP.RA117.000335

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Joel Basken

Natalie G Ahn

Andrew J Kavran

P577

2017-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29255136

http://www.w3.org/2001/XMLSchema#string

P932

5880111

http://www.w3.org/2001/XMLSchema#string